| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
TRACON Pharmaceuticals Inc (NASDAQ: TCON)
TCON Technical Analysis
5
| As on 12th Nov 2024 TCON STOCK Price closed @ 0.06 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.35 & Strong Sell for SHORT-TERM with Stoploss of 0.41 we also expect STOCK to react on Following IMPORTANT LEVELS. |
TCONSTOCK Price
| Open | 0.03 | Change | Price | % |
| High | 0.06 | 1 Day | 0.02 | 50.00 |
| Low | 0.03 | 1 Week | 0.01 | 20.00 |
| Close | 0.06 | 1 Month | -0.11 | -64.71 |
| Volume | 20559 | 1 Year | -0.54 | -90.00 |
| 52 Week High 3.01 | 52 Week Low 0.04 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| NVDA | 146.67 | 0.53% |
| AKTS | 0.10 | 11.11% |
| WORX | 2.12 | 116.33% |
| QUBT | 4.76 | 29.35% |
| LMDX | 0.02 | 0.00% |
| SMCI | 29.70 | 5.06% |
| MSTR | 397.28 | -16.16% |
| MARA | 23.81 | 22.17% |
| CRNC | 5.83 | 106.74% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| TCON Daily Charts |
TCON Intraday Charts |
Whats New @ Bazaartrend |
TCON Free Analysis |
|
|
TCON Important Levels Intraday
| RESISTANCE | 0.12 |
| RESISTANCE | 0.10 |
| RESISTANCE | 0.09 |
| RESISTANCE | 0.08 |
| SUPPORT | 0.04 |
| SUPPORT | 0.03 |
| SUPPORT | 0.02 |
| SUPPORT | 0.00 |
TCON Forecast November 2024
| 4th UP Forecast | 0.45 |
| 3rd UP Forecast | 0.32 |
| 2nd UP Forecast | 0.25 |
| 1st UP Forecast | 0.17 |
| 1st DOWN Forecast | -0.05 |
| 2nd DOWN Forecast | -0.13 |
| 3rd DOWN Forecast | -0.2 |
| 4th DOWN Forecast | -0.33 |
TCON Weekly Forecast
| 4th UP Forecast | 0.25 |
| 3rd UP Forecast | 0.19 |
| 2nd UP Forecast | 0.15 |
| 1st UP Forecast | 0.11 |
| 1st DOWN Forecast | 0.01 |
| 2nd DOWN Forecast | -0.03 |
| 3rd DOWN Forecast | -0.07 |
| 4th DOWN Forecast | -0.13 |
TCON Forecast2024
| 4th UP Forecast | 6.55 |
| 3rd UP Forecast | 4.47 |
| 2nd UP Forecast | 3.18 |
| 1st UP Forecast | 1.9 |
| 1st DOWN Forecast | -1.78 |
| 2nd DOWN Forecast | -3.06 |
| 3rd DOWN Forecast | -4.35 |
| 4th DOWN Forecast | -6.43 |
TRACON Pharmaceuticals Inc ( NASDAQ USA Symbol : TCON )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
TCON Business Profile
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. Address: 4350 La Jolla Village Drive, San Diego, CA, United States, 92122
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service